Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

Name: Recombinant Human Neuropilin-1 Fc Chimera Protein, CF
Brand: R&D Systems
SKU: 10455-N1

R&D Systems, Inc. a Bio-Techne Brand

Catalog # 10455-N1

Citations (2)

Product Datasheet / COA / SDS

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Source:	HEK293
Accession #:	NP_003864.4
Structure / Form:	Disulfide-linked homodimer
Applications:	Bioactivity

View Full Technical Details for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

Product Specifications for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

Source

Human embryonic kidney cell, HEK293-derived human Neuropilin-1 protein

Human Neuropilin-1 (Phe22-Lys852) Accession # NP_003864.4	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Phe22

Predicted Molecular Mass

120 kDa

SDS-PAGE

117-131 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human Neuripilin-1 Fc Chimera is immobilized at 1 µg/mL (100 µL/well), Recombinant Human VEGF 165 (Catalog # 293-VE) binds with an ED₅₀ of 0.25-1.5 ng/mL.

Scientific Data Examples for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

	Recombinant Human Neuropilin-1 Fc Chimera Protein Binding Activity. When Recombinant Human Neuropilin-1 Fc Chimera (Catalog # 10445-N1) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human VEGF 165 (Catalog # 293-VE) binds with an ED₅₀ of 0.25-1.5 ng/mL.
	Recombinant Human Neuropilin-1 Fc Chimera Protein SDS-PAGE. 2 µg/lane of Recombinant Human Neuropilin-1 Fc Chimera (Catalog # 10455-N1) was resolved by SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 117-131 kDa and 220-250 kDa, respectively.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10455-N1

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: Neuropilin-1

Neuropilin-1 (Npn-1, also known as neuropilin and CD304) is a 130-140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis (1-4). The full-length 923 amino acid (aa) human Npn-1 isoform 1 contains an 835 aa extracellular domain (ECD) that shows 92-95% aa identity with mouse, rat, bovine and canine Npn-1 (3, 4). The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain (c). C-terminally divergent splice variants with 704, 644, 609, and 551 aa lack the MAM and TM domains and are demonstrated or presumed to be soluble antagonists (1, 5-7). A 906 aa form lacks a TM segment, but secretion has not been found (8). The sema domains of Class III secreted semaphorins such as Sema3A bind Npn-1 a1a2 (9). Heparin, the heparin-binding forms of VEGF (VEGF 165, VEGF-B and VEGF-E), PlGF (PlGF2), and the C-terminus of Sema3 bind the b1b2 region (9, 10). Npn-1 and Npn-2 share 48% aa identity within the ECD and can form homo- and hetero-oligomers via interaction of their MAM domains (1). Neuropilins show partially overlapping expression in neuronal and endothelial cells during development (1, 2). Both neuropilins act as co-receptors with plexins, mainly plexin A3 and A4, to bind class III semaphorins that mediate axon repulsion (11). However, only Npn-1 binds Sema3A, and only Npn-2 binds Sema3F (1). Both are co-receptors with VEGF R2 (also called KDR or Flk-1) for VEGF 165 binding (1). Sema3A signaling can be blocked by VEGF 165, which has higher affinity for Npn-1 (12). Npn-1 is preferentially expressed in arteries during development or those undergoing remodeling (1, 2). Npn-1 is also expressed on dendritic cells and mediates DC-induced T cell proliferation (13). Npn-1 is a marker of CD4+ Treg cells and a population of CD8+ T-cells infiltrating solid tumors. Immunotherapies that block Npn-1 synergizes with anti-PD-1 to enhance CD8+ proliferation and response (14). There is evidence that Npn-1 with VEGF-A plays a role in stemness of breast cancer cell by activating Wnt/b-catenin pathway (15).

Item	Value
References	Bielenberg, D.R. et al. (2006) Exp. Cell Res. 312:584. Gu, C. et al. (2003) Dev. Cell 5:45. He, Z. and M. Tessier-Lavigne (1997) Cell 90:739. Soker, S. et al. (1998) Cell 92:735. Gagnon, M.L. et al. (2000) Proc. Natl. Acad. Sci. USA 97:2573. Cackowski, F.C. et al. (2004) Genomics 84:82. Rossignol, M. et al. (2000) Genomics 70:211. Tao, Q. et al. (2003) Angiogenesis 6:39. Gu, C. et al. (2002) J. Biol. Chem. 277:18069. Mamluk, R. et al. (2002) J. Biol. Chem. 277:24818. Yaron, A. et al. (2005) Neuron 45:513. Narazaki, M. and G. Tosato (2006) Blood 107:3892. Tordjman, R. et al. (2002) Nat. Immunol. 3:477. Leclerc, M. et al. (2019) Nat Commun. 10:3345. Zhang, L. et al. (2017) Cell Physiol. Biochem. 44:1251.
Entrez Gene IDs	8829 (Human); 18186 (Mouse); 246331 (Rat); 100286859 (Porcine)
Alternate Names	BDCA-4, BDCA4, CD304, CD304 antigen, DKFZp686A03134, DKFZp781F1414, NP1, NRP, NRP1, Neuropilin-1, Neuropilin1, VEGF165R, Vascular endothelial cell growth factor 165 receptor, neuropilin 1, transmembrane receptor

Citations for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF (2)

Showing 1 - 2 of 2 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF include:

Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay

N Gioelli et al. (2022), Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability Nature Communications, 13(1):4188.
PMID: 35858913
Species: Human
Sample Types: Whole Cells
Applications: Bioassay

J Huang et al. (2021), Overexpressed Neuropilin-1 in Endothelial Cells Promotes Endothelial Permeability through Interaction with ANGPTL4 and VEGF in Kawasaki Disease Mediators of Inflammation, 2021(0):9914071.
PMID: 34434074

There are no citations that match your criteria.

Showing 1 - 2 of 2 citations Showing All

Product Documents for Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS